Fezakinumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Fezakinumab ?
Monoclonal antibody
Type Whole antibody
Source Human
Target IL13
Clinical data
Legal status
?
Identifiers
CAS number 1007106-86-6 N
ATC code None
UNII 0S77U25XZ3 YesY
Chemical data
Formula C6408H9873N1706O2016S44 
Mol. mass 143.87 kDa
 N (what is this?)  (verify)

Fezakinumab is a human monoclonal antibody against interleukin-22,[1] designed for the treatment of psoriasis and rheumatoid arthritis.[2]

Wyeth discovered and initially developed the drug, and clinical development continued after that company was acquired by Pfizer. Fezakinumab, in combination with methotrexate, completed a phase II trial in rheumatoid arthritis, [3] but data was not released. Development was discontinued in August 2011.

References[edit]

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Fezakinumab". American Medical Association. 
  2. ^ page 6; http://www.pfizer.com/files/research/pipeline/2011_0228/pipeline_2011_0228.pdf
  3. ^ http://lmt.projectsinknowledge.com/Activity/index.cfm?showfile=b&jn=2016&sj=2016.05&sc=2016.05.4